Mesoblast Limited (MEOBF)
USD 1.03
(0.0%)
USD 1.03
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 118.7 Million USD | 2.08% |
| 2023 | 116.49 Million USD | 8.97% |
| 2022 | 106.9 Million USD | 1.34% |
| 2021 | 105.49 Million USD | 6.22% |
| 2020 | 99.31 Million USD | 22.18% |
| 2019 | 81.28 Million USD | 36.85% |
| 2018 | 59.39 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 114.34 Million USD | -6.27% |
| 2024 Q2 | 121.99 Million USD | 2.39% |
| 2024 Q1 | 119.14 Million USD | 2.22% |
| 2024 Q4 | 118.92 Million USD | 4.0% |
| 2024 FY | 118.7 Million USD | 1.89% |
| 2023 Q2 | 111.78 Million USD | 1.96% |
| 2023 Q1 | 109.63 Million USD | 2.55% |
| 2023 FY | 116.49 Million USD | 8.97% |
| 2023 Q4 | 116.55 Million USD | 1.7% |
| 2023 Q3 | 114.6 Million USD | 2.53% |
| 2022 FY | 106.9 Million USD | 1.34% |
| 2022 Q3 | 104.65 Million USD | 1.43% |
| 2022 Q4 | 106.9 Million USD | 2.15% |
| 2022 Q1 | 107.19 Million USD | 1.61% |
| 2022 Q2 | 103.17 Million USD | -3.75% |
| 2021 Q2 | 99.72 Million USD | -1.29% |
| 2021 Q1 | 101.02 Million USD | 1.72% |
| 2021 FY | 105.49 Million USD | 6.22% |
| 2021 Q4 | 105.49 Million USD | 3.59% |
| 2021 Q3 | 101.84 Million USD | 2.12% |
| 2020 Q3 | 95.77 Million USD | 1.56% |
| 2020 Q4 | 99.31 Million USD | 3.7% |
| 2020 FY | 99.31 Million USD | 22.18% |
| 2020 Q1 | 89.17 Million USD | 9.7% |
| 2020 Q2 | 94.29 Million USD | 5.75% |
| 2019 Q1 | 61.15 Million USD | 2.97% |
| 2019 Q4 | 81.28 Million USD | 2.15% |
| 2019 Q2 | 63.48 Million USD | 3.8% |
| 2019 Q3 | 79.57 Million USD | 25.35% |
| 2019 FY | 81.28 Million USD | 36.85% |
| 2018 FY | 59.39 Million USD | 0.0% |
| 2018 Q4 | 59.39 Million USD | 89.03% |
| 2018 Q3 | 31.42 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -188.087% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -2779.71% |
| SQZ Biotechnologies Company | 27.47 Million USD | -332.094% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -173.674% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -298.763% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -12417.562% |
| Genus plc | 233.1 Million USD | 49.077% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -3950.672% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -8734.611% |
| Marizyme, Inc. | 18.71 Million USD | -534.168% |
| ContraFect Corporation | 2.88 Million USD | -4020.112% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -15726.722% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -87510.187% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -8107.07% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -5003.298% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -1997.791% |
| MultiCell Technologies, Inc. | 202.58 USD | -58594240.014% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -106.475% |
| EV Biologics, Inc. | 1.49 Million USD | -7841.15% |
| Q BioMed Inc. | 4.1 Million USD | -2788.101% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -258.601% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -18739.033% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -9563.317% |
| Biomind Labs Inc. | 735.54 Thousand USD | -16037.816% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 30.805% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -813.291% |
| Skye Bioscience, Inc. | 4.61 Million USD | -2471.908% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -13266.2% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -83776.549% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -1921.778% |
| IMV Inc. | 28.88 Million USD | -310.957% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -461428.108% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -5155.996% |
| GB Sciences, Inc. | 1.75 Million USD | -6646.998% |
| Alpha Cognition Inc. | 1.22 Million USD | -9626.576% |
| HST Global, Inc. | 98.31 Thousand USD | -120629.883% |
| CSL Limited | 12.18 Billion USD | 99.026% |
| Halberd Corporation | 150 Thousand USD | -79033.609% |
| Enzolytics Inc. | 996.33 Thousand USD | -11813.669% |
| Resverlogix Corp. | 6.49 Million USD | -1728.692% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -24758.725% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -46341.365% |
| argenx SE | 20 Million USD | -493.502% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -160.536% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -4282.186% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1160784.244% |
| Genscript Biotech Corporation | 417.73 Million USD | 71.585% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -59067.97% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -4850.545% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -51668.458% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -75.481% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -3822.436% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -32898.92% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -483.926% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -79750.131% |
| BioStem Technologies, Inc. | 4.71 Million USD | -2419.421% |
| ONE Bio Corp. | 19.71 Million USD | -502.081% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -47345.625% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -47624.515% |
| Agentix Corp. | 50 Thousand USD | -237300.828% |
| LadRx Corporation | 33.6 Thousand USD | -353111.968% |
| Cell Source, Inc. | 9.25 Million USD | -1182.669% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -15596.877% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -15596.877% |
| NovAccess Global Inc. | 2.19 Million USD | -5295.768% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1578.264% |
| Itoco Inc. | 228.37 Thousand USD | -51875.643% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -56162.787% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -2282.107% |
| Kadimastem Ltd | 891.22 Thousand USD | -13218.778% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -29438.561% |
| CytoDyn Inc. | 30.07 Million USD | -294.668% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -24410.497% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -33636.372% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1417.916% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -96798.297% |
| Rebus Holdings, Inc. | 310 Thousand USD | -38190.456% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -2406.723% |
| International Stem Cell Corporation | 4.17 Million USD | -2741.082% |
| Bioxytran, Inc. | 1.92 Million USD | -6066.255% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -190085.4% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -5342.726% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1327.374% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -1282.649% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -7531.116% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -44191.199% |
| Neutra Corp. | 54.15 Thousand USD | -219082.388% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -6386.361% |
| PureTech Health plc | 25.51 Million USD | -365.273% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -9595.956% |
| IXICO plc | 472.02 Thousand USD | -25047.167% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -665.76% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -90.644% |
| CSL Limited | 12.18 Billion USD | 99.026% |
| Cellectis S.A. | 92.77 Million USD | -27.942% |